Johnson & Johnson (NYSE: JNJ ), one of the prominent global healthcare behemoths around, which experienced quite an underwhelming 2024, appears to have gotten going in the first half of 2025. To elaborate, on a YTD basis, the stock has generated returnsAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not rec ...